INNATE PHARMA SA-SPONS ADR (IPHA) Stock Analyst Earnings Estimates
NASDAQ:IPHA - Nasdaq - US45781K2042 - ADR
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 12.112M -78.43% | 49.58M 309.35% | 51.901M 4.68% | 35.948M -30.74% | 72.489M 101.65% | 107.42M 48.19% | 105.53M -1.76% | 144.85M 37.26% | 205.38M 41.79% | 248.75M 21.12% | 324.75M 30.55% | |
| EBITDA YoY % growth | -43.229M -174.69% | 28.98M 167.04% | -7.578M -126.15% | -47.739M -529.96% | 24.146M 150.58% | 47.035M 94.79% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -47.825M -4,532.34% | -16.425M 65.66% | -12.669M 22.87% | -33.49M -164.34% | -1.828M 94.54% | 11.162M 710.66% | -34.488M -408.97% | 31.102M 190.18% | 89.854M 188.90% | 141.7M 57.70% | 174.41M 23.08% | |
| Operating Margin | -394.86% | -33.13% | -24.41% | -93.16% | -2.52% | 10.39% | -32.68% | 21.47% | 43.75% | 56.96% | 53.71% | |
| EPS YoY % growth | N/A -53.38% | N/A 72.93% | N/A -169.82% | -0.37 28.59% | -0.03 92.04% | 0.27 1,022.23% | N/A | N/A | N/A | N/A | N/A |
All data in EUR
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in EUR
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2021 Q2Q % growth | -0.59 -645.50% | % | ||
| Q4 2020 Q2Q % growth | -0.08 | % | ||
| Q3 2020 Q2Q % growth | -0.08 | % | ||
| Q2 2019 Q2Q % growth | 0.20 | 0.32 | -0.12 | -38.12% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2024 Q2Q % growth | 8.293M -76.54% | % | ||
| Q4 2023 Q2Q % growth | 16.557M 99.27% | % | ||
| Q2 2023 Q2Q % growth | 35.344M -14.36% | % | ||
| Q4 2022 Q2Q % growth | 8.309M 118.20% | % | ||
| Q2 2022 Q2Q % growth | 41.271M 397.00% | % | ||
| Q4 2021 Q2Q % growth | 3.808M -85.53% | % | ||
| Q2 2021 Q2Q % growth | 8.304M -72.17% | % | ||
| Q4 2020 Q2Q % growth | 26.31M 51.33% | 27.379M | -1.069M | -3.90% |
| Q3 2020 Q2Q % growth | 22.86% | 27.379M | % | |
| Q2 2020 Q2Q % growth | 29.84M -42.16% | % | ||
| Q4 2019 Q2Q % growth | 17.386M | 22.285M | -4.899M | -21.98% |
| Q2 2019 Q2Q % growth | 51.588M | 58.735M | -7.147M | -12.17% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | N/A | N/A | 0% | -2.31% |
| Revenue | N/A | N/A | 0.75% | 0.75% |